Article and Video CATEGORIES
Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered this past year (virtually) to review information presented at ASCO and ESMO 2021, regarding patients dealing with a Lung Cancer diagnosis.
For this series, the doctors discuss new trials for patients with NSCLC and SCLC. The video discussions cover the following topics:
- IMpower010: Atezolizumab after Chemo in Non-Small Cell Lung Cancer
- Surgical Outcomes and Checkmate 816: Addition of Nivolumab in Early Stage Non-Small Cell Lung Cancer
- FDA Analysis of Immunotherapy With or Without Chemo in Advanced NSCLC and Low PDL-1
- Poseidon Trial: Durvalumab +/- Tremelimumab vs. Chemo Alone
- Carbo/Pemetrexed/Pembro and Acquired Resistance in EGFRm+ or ALK+ NSCLC
- Immune Therapy for Brain Metastases
- CodeBreak 100: Sotorasib in KRAS G12C Mutation
- Amivantamab and Mobocertinib for EGFR Exon 20
- Amivantamab + Lazertinib in EGFR Mutation, Patritumab Deruxtecan in EGFR Mutation-Positive Acquired Resistance
- MYLUNG Consortium: Overall Biomarker Testing
- Lurbinectedin in Small Cell Lung Cancer and the Failed Atlantis Trial
- Circulatory Tumor DNA
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
Next Previous linkPrevious PostNext Post
The forum was a big success. If you weren't able to attend the live session we'll have an on-demand version available soon.
If you have questions that weren't addressed please ask...
Hi Everyone, I'm glad you have found this thread and sorry that you need to be here.
We've got the forum up for on-demand streaming. This full version will be...
Hi JGromo, Welcome to Grace. I'm so sorry your dad and by extension, you are going through this. If it helps, I know how you feel. My husband is going through...
I agree that not all docs are good communicators! Remember they are people just like us, filling a very important role. I echo Janine's comment to ask questions here -- our...
While no one can give advice or recommend treatments on a forum our faculty can be invaluable when talking about current thought and practices.
This is the response via email...
I wanted to…